Drug Type Autologous CAR-T |
Synonyms Anti-CD19 Autologous CAR-T Cell (920th Hospital), OlyCAR 019, OlyCAR019 |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Leukemia | Phase 2 | China | 01 Jul 2023 | |
CD19 Expressing Malignancies | Phase 2 | China | 01 Jul 2023 | |
B-Cell Lymphoma | Phase 1 | China | 01 Apr 2020 | |
B-Cell Malignant Neoplasm | Phase 1 | China | 01 Apr 2020 | |
B-Cell Malignant Neoplasm | Phase 1 | China | 01 Apr 2020 | |
Pre B-cell acute lymphoblastic leukemia | Phase 1 | China | 01 Apr 2020 | |
Pre B-cell acute lymphoblastic leukemia | Phase 1 | China | 01 Apr 2020 |